Hematologic Malignancy
Chronic Leukemia
CI-CAN-00000764Explore in graph →
Hematologic410 active trials10 approved drugs59 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000764Explore in graph →
Clinical trials
1,704 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (302)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06651970 | Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure | recruiting | Phase 4 | 60 | AstraZenecaINDUSTRY | 6 | Sep 24, 2026 | clinicaltrials |
| NCT07218341 | A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | recruiting | Phase 4 | 150 | Eli Lilly and CompanyINDUSTRY | 17 | Sep 22, 2026 | clinicaltrials |
| NCT06876649 |
| A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib |
| recruiting |
| Phase 4 |
| 787 |
| Eli Lilly and CompanyINDUSTRY |
| 8 |
| Mar 2, 2026 |
| clinicaltrials |
| NCT06876662 | A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma | recruiting | Phase 4 | 279 | Eli Lilly and CompanyINDUSTRY | 8 | Mar 2, 2026 | clinicaltrials |
| NCT04790045 | Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens(LymBIO) | not yet recruiting | Phase 4 | 30 | Paolo GhiaOTHER | 0 | Oct 3, 2023 | clinicaltrials |
| NCT05316831 | Immune Response After Pneumococcal Vaccination in Patient With Chronic Lymphocytic Leukemia | completed | Phase 4 | 77 | Region Örebro CountyOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT05367765 | A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase | not yet recruiting | Phase 4 | 2,400 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 10, 2022 | clinicaltrials |
| NCT05353205 | A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. | unknown | Phase 4 | 200 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 29, 2022 | clinicaltrials |
| NCT04677439 | Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure | unknown | Phase 4 | 200 | Shenzhen Second People's HospitalOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT01283386 | A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status | terminated | Phase 4 | 26 | Hoffmann-La RocheINDUSTRY | 1 | Mar 14, 2019 | clinicaltrials |
| NCT01271010 | A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status | terminated | Phase 4 | 89 | Hoffmann-La RocheINDUSTRY | 1 | Mar 20, 2018 | clinicaltrials |
| NCT03332511 | Efficacy and Safety of Nilotinib in CML-CP(ENESTKorea) | completed | Phase 4 | 110 | Seoul National University HospitalOTHER | 0 | Nov 6, 2017 | clinicaltrials |
| NCT01660906 | Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib | completed | Phase 4 | 39 | Bristol-Myers SquibbINDUSTRY | 5 | Nov 22, 2016 | clinicaltrials |
| NCT01255644 | Antiviral Treatment of Chronic Lymphocytic Leukemia(VGCV-CLL) | completed | Phase 4 | 20 | Medical University of ViennaOTHER | 1 | Jul 21, 2015 | clinicaltrials |
| NCT01056510 | A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe) | completed | Phase 4 | 357 | Hoffmann-La RocheINDUSTRY | 8 | Jun 25, 2015 | clinicaltrials |
| NCT00919321 | The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLL(KLL2) | completed | Phase 4 | 32 | Tampere University HospitalOTHER | 1 | Feb 19, 2014 | clinicaltrials |
| NCT01339988 | Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT) | unknown | Phase 4 | 10 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 0 | Apr 21, 2011 | clinicaltrials |
| NCT00131313 | Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. | unknown | Phase 4 | 180 | East Valley Hematology and Oncology Medical GroupOTHER | 1 | Aug 18, 2005 | clinicaltrials |
Data updated 4 days agoSource updated Sep 24, 2026source: clinicaltrials